Using Zepbound alongside Taltz produced better joint-disease responses than Taltz alone at one year in adults with active psoriatic arthritis and excess weight. The new TOGETHER-PsA results make a useful case for studying arthritis and obesity care together. They do not establish that Zepbound treats arthritis on its own.
The central finding in the November 11 report in Arthritis & Rheumatology was an estimated ACR50 response rate of 43.7% with the combination versus 15.7% with Taltz alone at week 52. Understanding that result requires three distinctions: joint response versus weight loss, the planned primary endpoint versus exploratory follow-up, and modeled benefit versus what happens when people stop treatment.
What did the trial actually compare?
TOGETHER-PsA randomized 271 adults: 138 to Taltz plus Zepbound and 133 to Taltz alone. Taltz is ixekizumab; Zepbound is tirzepatide. Both groups received counseling on a reduced-calorie diet and increased physical activity, according to Lilly’s announcement, which is sponsor evidence. There was no tirzepatide-only group and no comparison against another obesity medicine.
The registered eligibility criteria required active psoriatic arthritis and either BMI of at least 30, or BMI from 27 to below 30 with a qualifying weight-related condition. Participants were aged 18–80; type 1 diabetes and insulin-treated type 2 diabetes were excluded, but diabetes was not excluded altogether. People who had previously used either study medicine were excluded. The trial therefore tested starting the treatments together, rather than adding Zepbound after months on Taltz. This was not a general joint-pain study.
The original ACR conference abstract reports an average age of 55 and average BMI of 37.6. Both medicines were given at US-approved doses within the research protocol. The study was open-label, so participants knew their treatment, although the journal abstract describes blinded assessors. That matters when interpreting self-reported symptoms and quality of life.
Joint response and weight loss are separate outcomes
ACR50 is a composite response criterion. It requires at least 50% improvement in tender and swollen joint counts, plus improvement in several other disease measures. It does not mean that 43.7% of participants were cured, nor does it describe a percentage of body weight lost.
The sponsor’s one-year results table separates the outcomes:
| Outcome | Taltz + Zepbound | Taltz alone |
|---|---|---|
| ACR50 joint-disease response | 43.7% | 15.7% |
| At least 10% weight reduction | 85.7% | 6.7% |
| Both outcomes together | 39.2% | 1.7% |
The ACR50 gap is 28 percentage points. That absolute difference is easier to interpret than the sponsor’s “nearly three times” framing. The weight row describes the proportion reaching a threshold, not average weight loss. The combined endpoint is stricter: a person must meet both criteria.
The registered primary test was that combined endpoint at 36 weeks. These new 52-week analyses were prespecified but exploratory, without adjustment for testing many comparisons. They extend the evidence on durability; they should not be described as a second confirmatory primary result.
Why the analysis assumptions matter
The ACR figure captions identify a hypothetical estimand in the modified intention-to-treat population. Researchers modeled what would happen if treatment discontinuation or prohibited medication use had not occurred, using multiple imputation for missing data. The reported rates therefore are not simply observed counts divided by everyone randomized. Our trial-estimand guide explains the broader distinction.
The abstract says 71.6% completed study treatment. That does not mean the remainder all stopped because of adverse effects, but it makes the handling of discontinuation consequential. Readers need both the estimated response under the analysis assumptions and evidence about how sustainable the regimen is in practice.
The accessible journal abstract, conference text and sponsor table were inspected for this report. The full journal paper, supplement and complete statistical analysis plan were unavailable for review. Detailed sensitivity analyses and full safety tables therefore remain outside this article’s scope.
Better outcomes do not establish the mechanism
Lilly highlights an early separation in joint responses before substantial weight loss. That timing is interesting, but it does not isolate a direct anti-inflammatory effect of tirzepatide. Without a design that separates weight change from other effects, the trial cannot tell readers how much benefit came through each pathway.
Nor should these results be combined with trials of osteoarthritis, a different condition, to promise a general arthritis benefit. The practical contribution is narrower: treating obesity alongside established psoriatic-arthritis therapy may improve more than weight alone in this selected population.
What changes for care discussions?
The US Taltz label includes active psoriatic arthritis in adults. The US Zepbound label covers weight management and a specified sleep-apnea indication, not psoriatic arthritis. This research announcement is not a new approval or an instruction to add, stop or switch medicines. Our tirzepatide profile covers its wider treatment context.
The sponsor reports mostly mild-to-moderate adverse events, including gastrointestinal symptoms in the combination group. That summary cannot exclude uncommon or longer-term harms. Existing warnings still matter: Taltz carries infection-related precautions, while Zepbound has gastrointestinal and other risks, including a boxed thyroid-tumor warning. Our tolerability guide explains why a benefit headline needs safety context.
For readers managing both conditions, useful questions include how joint activity, daily function, weight and tolerability will each be assessed, and how the care teams will coordinate follow-up. Our appointment guide helps organize that discussion. The next evidence to look for is the full analysis of discontinuations, safety and outcomes beyond one year—not a promise that every person will achieve the trial’s modeled response.


